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ABSTRACT

Samuel, Rittu Elsa. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2019. Identification of New Metabolic Mutations that Enhance the CellKilling Effect of Hydroxyurea, A Clinically Used Drug with Multiple Implications

Cancer is one of the leading causes of death and a worldwide health issue. Intensive studies
have been conducted in the past to unearth new anti-cancer agents. One such antiproliferative drug is hydroxyurea (HU). HU has been used in clinics for ≥ 100 years to treat
various neoplastic and non-neoplastic diseases. Although newer agents have been
developed, as a WHO-enlisted essential medicine, it remains the staple drug for the
management of chronic myeloproliferative disorders and sickle cell anemia. A better
understanding of the HU-induced cell death may improve or expand the therapeutic
spectrum of this clinically important drug. HU arrests DNA replication and causes DNA
damage in proliferating cells by inhibiting ribonucleotide reductase (RNR), which is
thought to be responsible for its cytotoxic and hence the therapeutic effects. While studying
the DNA replication checkpoint activated by HU, we unexpectedly discovered a new set
of "non-chk" mutants in fission yeast that are highly sensitive to HU. Our preliminary and
published data have shown that these non-chk mutants are not killed by arrested DNA
replication but by a previously unknown mechanism involving perturbations of various
metabolic pathways. This study is to take the unbiased genetic approach to characterize an
extensive collection of the "non-chk" mutants that are highly sensitive to HU. In addition
iii

to the previously identified erg11-1 and hem13-1 mutations, we have identified in this
study new mutations in the two genes erg7 and erg25 encoding the enzymes lanosterol
synthase and C-4 methylsterol oxidase in the ergosterol biosynthesis pathway that
dramatically sensitizes the cells to HU. Since fission yeast is an established model for
studying the cellular mechanisms that are conserved in humans, this study may help to
understand the novel cell-killing mechanism of HU and hence promote therapeutic
innovations.
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INTRODUCTION
Eukaryotic DNA Replication
‘Le rêve d’une bactérie doit devenir deux bactéries’
(The dream of a bacterium is to become two bacteria)
This is a poetic statement by the French biologist, François Jacob used to describe the cell
cycle regulation [1]. The cell cycle is a regulated series of events in which a cell grows,
develops and divides into two new identical cells. The most important phase of the cell
cycle is the replication of the genetic material, deoxyribonucleic acid (DNA) called the
DNA synthesis or S-phase. As complex and unique the helical structure of DNA is, as is
the process of DNA replication. Various proteins play a vital role in a coordinated manner
for initiating the copying process and synthesizing two new strands by adding
complementary nucleotides to the separated parent DNA strands efficiently and with
utmost fidelity [2]. However, DNA is under constant assault from a variety of endogenous
and exogenous factors like ultraviolet (UV) radiations from the sunlight, reactive oxygen
species (ROS) generated from normal cellular metabolism or exposure to different drugs,
which may cause replication stress. Under these stressful conditions, mistakes may happen
while replicating, affecting the genome integrity and leading to mutations. And it has been
revealed that around 42 diseases are caused by mutations in genes involved in the
regulation of this highly challenging process of DNA replication [3, 4, 5]. To combat this,
there are a variety of safeguard systems like checkpoint mechanism described below which
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counteract and protect DNA replication forks from collapsing through various
mechanisms [5, 6].

The DNA Replication Checkpoint
Cell cycle checkpoints control the normal sequence of events during the cell cycle, which
ensures completion of DNA replication, the inheritance of genomic information, and cell
survival [7, 11, 13]. Two DNA checkpoint signaling pathways have been defined in the
fission yeast Schizosaccharomyces pombe. The first is the DNA replication
checkpoint (DRC) which is activated during the S-phase in the presence of arrested
replication forks, nucleotide depletion or damage to DNA templates. The other is the DNA
damage checkpoint (DDC), which is activated during the G2 phase by DNA damage caused
by internal or external sources of DNA damaging agents [8, 15]. The activated checkpoints
slow down the replication process while stimulating the DNA damage repair process [9].
In theory, there are three types of checkpoint proteins namely the sensors, the mediators
and the effectors that are activated in response to replication stress or DNA damage (Figure
1) [11, 12].

Damage
Signals

Sensors

Mediator

Effector

Figure 1: Central dogma for cell cycle checkpoints

The key players of the DRC are the proteins of the phosphoinositide-3-kinase-like kinase
(PIKK) family. The major role of sensing the damage and phosphorylating the effector
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kinases is played by Rad3 (human ATR) with its regulatory subunit Rad26 (human
ATRIP). Rad3-Rad26 complex identifies RPA coated ss-DNA generated at the perturbed
forks. Another trimeric complex called 9-1-1 (Rad9-Rad1-Hus1), related to proliferating
cell nuclear antigen (PCNA), is loaded onto DNAs associated with the perturbed forks with
the help of Rad17 and the replication factor C complex RFC2-5 [10, 11]. Mrc1 (mediator
of replication checkpoint 1) acts as an adaptor in the DRC pathway for recruiting the
downstream effector kinase Cds1. Mrc1 is phosphorylated by Rad3 in response to stalled
replication forks [8, 11]. Following the recruitment of inactivated Cds1, Rad3
phosphorylates and hence activates Cds1 kinase, which in turn phosphorylates various
downstream targets and is responsible for stimulating most of the cellular responses under
replication stress [10, 16].

Activation of the DRC
DNA damaging agents are capable of inducing replication stress and stalls the replication
fork by damaging the DNA template. This leads to the formation of different
macromolecular structures, which are sensed by the checkpoint sensors and thus, activates
the DRC. The compounds used in this study for activating DRC are described below:

Hydroxyurea (HU)
The Therapeutic Effects of HU
In 1869, this small compound, hydroxylated urea called as hydroxycarbamide or
hydroxyurea was synthesized by Dressler and Stein [31]. In 1928, the antimetabolite

3

property of this agent was identified. Since then it has been a drug of great scientific
interest. It has been used as a non-alkylating antineoplastic, antiviral, antifungal and a cell
cycle synchronization agent [32]. Currently, it is used for the treatment of skin cancer,
chronic myeloproliferative diseases and a variety of solid tumors owing to its cytotoxic
properties [28, 29]. Even though newer therapeutics have been developed, HU remains the
only FDA approved safe and effective drug until 2017 for treating the complications
associated with sickle cell anemia (SCA) and reducing the need for blood transfusion [25,
26]. Because HU is a safe, efficacious and cost-effective for multiple clinical implications
and haemoglobinopathies, it was enlisted as an ‘essential medicine’ by the World Health
Organization (WHO) [24].

The Primary Cellular Target of HU
The well-established cellular target of HU is the enzyme ribonucleotide reductase (RNR),
which is required for the synthesis of deoxyribonucleotides (dNTPs) by catalyzing the
reduction of NDPs [31]. This is the rate limiting step in the DNA replication process and
RNR is therefore highly regulated during the cell cycle. The structure of RNR consists of
two subunits, a larger R1 subunit and a smaller R2 subunit. The R1 subunit includes the
substrate specificity sites, allosteric sites for substrate binding while the R2 subunit carries
a tyrosyl free radical with a di-ferric iron center. By an incompletely understood
mechanism, this tyrosyl radical is transferred into the R1 subunit to generate the thiyl
radical, which is required for the catalysis of this enzyme [28, 21, 32].
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HU inactivates the tyrosyl radical and thus, inhibits RNR (Figure 2) [27, 30]. This leads
to decreased synthesis of dNTPs, which induces replication stress and activates the DRC
[30].

Figure 2: Structure of ribonucleotide reductase
The activated DRC inhibits cell devision so that the cells have enough time for the DNA
replication and repair [22, 32]. The activated DRC also upregulates RNR to promote the
dNTP production. Therefore, overexpression of Suc22, the smaller subunit of RNR, has
been reported to suppress the HU sensitivity of the DRC mutants [20, 21, 30]. Other
protective responses activated by DRC include mitosis delay and suppression of late firing
origins, which work in concert to promote cell survival under the replication stress induced
by HU [21].

Secondary Target(s) of HU
Extensive studies have been carried out in the past to better understand the cell-killing
mechanisms of HU. As explained above, HU reversibly inhibits RNR and activates the
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DRC for proper resumption of DNA replication and cell survival under stress. Defects in
DRC sensitize the cells to HU. However, it has been found that the DRC remains functional
in some mutants that are sensitive to HU and the cell death is involved in cytokinesis arrest
or oxidative stress in the presence of mutations in heme or sterol biosynthesis pathways.
Unexpected discovery of such mutants provides an insight to the novel cell-killing
mechanisms of HU [48]. To distinguish the new collection of HU sensitive (hus) mutants,
they were named as ‘non-chk’ mutants as the DRC remains functional in these mutants.
Five non-chk mutations of various metabolic pathways have been identified that includes
erg11 (ergosterol biosynthesis pathway), mvd1 and hcs1 (mevalonate pathway), hem13
and ccr1 (heme biosynthesis pathway). The mechanism behind the cytotoxic effect of HU
in these non-chk mutants was clearly not due to the RNR inhibition, which induces S-phase
arrest and DRC activation. This raises an interesting question of whether HU has a
secondary cellular target(s). Characterization of the non-chk mutants may help to
understand the mechanism behind the HU induced cell death.
It has been reported that a missense mutation G189D in the erg11 gene encoding the
enzyme sterol-14α-demethylase in the ergosterol biosynthesis highly sensitizes the cells to
HU. The mutation likely decreases the production of the end product ergosterol that is
required for cell membrane fluidity. In the presence of sterol deficiency, HU affects the
cytokinesis phase. This HU induced cytokinesis arrest was found stable that likely causes
cell death in the mutant. Erg11 is also an established target for antifungal therapies. Since
the sterol biosynthesis process are highly conserved in eukaryotes, we found that various
combinations of HU with the inhibitors of erg11 (antifungal azoles) have a synergistic cellkilling effects on fission yeast as well as the fungal pathogen C. albicans [20].
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A single mutation T263D in the hem13 gene encoding the enzyme coproporphyrinogen
oxidase (CPOX) required for heme biosynthesis has also been found that is responsible for
the cytotoxic effect to HU. Unlike the erg11 mutant, reduced heme production promotes
oxidative stress, which likely explains the HU-induced cell inviability in this hem13
mutant. Unlike the checkpoint mutants, the hem13 cells were arrested in the G2/M phase.
In support of this cell-killing mechanism, combining HU with the inhibitor of Hem13
(sampangine), also suppressed the cell growth in wild type cells [47]. Thus, screening more
non-chk mutants to better understand the HU-induced cell lethality may help to improve
the HU-based chemotherapies.

Methyl Methane Sulfonate (MMS)
DNA alkylating agents are a major class of drugs used for the treatment of cancer. MMS,
a monofunctional alkylating agent, is used in this study to activate the checkpoints and as
described below to specifically differentiate between the chk and the non-chk mutants.
MMS alters the bases in the DNA template by methylation and forms DNA adducts. The
major product is a non-mutagenic N7-methylguanine (7meG), which on depurination
forms a toxic product. Other highly toxic product formed is N3-methyladenine, which
inhibits DNA synthesis by blocking DNA polymerases. Other minor lesions formed,
capable of blocking replication are N1-methyladenine and N3-methylcytosine [17, 18, 19].
(Figure 3)
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Figure 3: Toxic or mutagenic products formed after treatment with MMS [19]

Ergosterol Biosynthesis
Ergosterol is a sterol similar to mammalian cholesterol and an essential component of the
cell membrane in fungi. It is required for maintaining the fluidity, stability and integrity of
the cell membrane. The structure of ergosterol and cholesterol are different and therefore,
some enzymes in the ergosterol biosynthesis pathway are targeted for antifungal therapies.
The ergosterol biosynthesis is a tightly regulated process that consists of two pathways, the
mevalonate pathway and the late mevalonate pathway. There is an alternate pathway as
well, which is activated in response to increase in lanosterol levels in the late pathway and
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the product in this pathway is cytostatic. In the mevalonate pathway, farnesyl
pyrophosphate is formed from Acetyl CoA that is required for the synthesis of other
biosynthetic molecules. The rate limiting step in this pathway is the synthesis of
mevalonate from 3-hydroxy-3-methylglutarate CoA (HMG-CoA) by the enzyme
HMG-CoA reductase. The end product of this pathway is farnesyl pyrophosphate, which
is also required for the production of squalene and intermediate products of other metabolic
pathways. The late pathway includes the synthesis of ergosterol from squalene. Decrease
in ergosterol levels affects the cell membrane related functions. Even though the structures
of ergosterol and cholesterol are different, the majority of genes involved in the sterol
biosynthesis are conserved [42].
Statins, the widely used drugs for hyperlipidemia inhibits the HMG CoA reductase in the
mevalonate pathway. This inhibition also affects the production of intermediate molecules
that are needed for other biosynthetic pathways like ubiquinone, dolichol, and isoprenoids
(Figure 4). This likely explains the various side-effects associated with statins. Hence,
developing drug molecules that only affect the production of the downstream products
from squalene in the late mevalonate pathway may be more promising and productive [40].
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Figure 4: Ergosterol biosynthetic pathway.
Different parts of ergosterol biosynthesis showing the enzymes involved and their inhibitors. The
box in the left represents the ‘mevalonate’ pathway in which farnesyl pyrophosphate is the end
product and also an intermediate for production of other biosynthetic molecules. The box in the
middle represents the ‘late’ pathway in which ergosterol is the end-product. The box in the right
represents an alternate pathway which is activated in response to increased levels of lanosterol. The
red text indicates different drugs used to target specific enzymes.
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Schizosaccharomyces pombe, the model organism
The fission yeast Schizosaccharomyces pombe was used as the model organism in this
study. S. pombe is a well-established model for studying the cell cycle related mechanisms
that are highly conserved in eukaryotes. It offers several technical advantages for this study.
For example, it is easy to handle as they grow rapidly and the whole yeast genome
sequences have been identified. The two types of hus mutants that are investigated in this
study are described below.
Chk Mutants
These hus mutants have mutations in genes involved in the DRC. The characteristics of a
chk mutant include a) they are highly sensitive to HU as well as the DNA damaging agents
MMS and UV, b) their hus phenotype can be suppressed by overexpressing Suc22, the
small subunit of RNR, and c) the chk mutant cells are arrested in the S-phase by HU.
Therefore, the rad3 and chk1 null mutants were used as checkpoint mutant controls in the
spot assay throughout this study.
Non-chk Mutants
These mutants have mutations in metabolic genes, not the DRC signaling pathway. The
characteristics of the non-chk mutants are a) they are highly sensitive to chronic, not
acute treatment with HU, b) they are resistant to DNA damage caused by MMS and UV,
c) they cannot be rescued by Suc22 overexpression, and d) the non-chk cells are arrested
by HU in the G2/M, not the S-phase of the cell cycle. Already identified and
characterized non-chk mutants used in this study includes erg11, hem13, ccr1, hcs1 and
mvd1 mutants.
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SPECIFIC AIMS
1. Screening of new non-chk mutants that are sensitive to HU
2. Elimination of known and bystander mutations
3. Determination of linkage groups
4. Identification of the mutations in two non-chk mutants, M7 and M38
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SIGNIFICANCE
As discussed in the introduction, HU is the reversible inhibitor of RNR. Treatment of
proliferating cells with HU slows down the replication process and activates the DRC to
upregulate RNR, which promotes DNA synthesis. However, recent studies showed that
HU treatment of cells with mutations in various metabolic pathways may generate
cytokinesis arrest or oxidative stress, which ultimately lead to the cell death.
In this study, the main question we have tried to address was how many more cellular
metabolic pathways can be perturbed in order to sensitize the cells to HU. To this end, we
have used the unbiased genetic approach to identify new non-chk mutations that sensitize
the cells to HU. Since fission yeast is an established model for studying the cellular
mechanisms that are conserved in humans, the mutations identified during the course of
this study may help to promote the therapeutic innovations for the treatment of cancer or
fungal infections.
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MATERIALS AND METHODS
Yeast Strains, Plasmids and Chemicals
Standard methods and genetic techniques were used for the S. pombe cell culture and the
genetic screening. All yeast strains used in this study are listed in Table 1. The collection
of non-chk mutants were all derived from the wild type S. pombe YJ374 strain after
treatment with methyl nitrosoguanidine (MNNG) to generate random mutations in the S.
pombe genome [34]. The media used for culturing the cells were YE6S (0.5% yeast extract,
3% glucose with the six essential supplements, adenine, uracil, histidine, lysine, leucine,
arginine) or the synthetic EMM media with all or lacking one of the appropriate
supplements. Malt extract (ME) medium was used for mating purposes. The plasmids and
PCR primers used in this study are listed in Table 3 and 4, respectively. All plasmids and
mutations were confirmed by DNA sequencing (Retrogen, San Diego, CA). HU (Sigma)
was prepared in distilled water as a 1.0 M stock solution. MMS was used directly from
99% stock solution. Phloxin B dye was used as an indicator of cell lethality.

Drug Sensitivity Test
Drug sensitivity tests were usually assessed by the spot assay. This assay involves serial
dilution (5 times or 10 times) of logarithmically growing fission yeast culture of 1 OD
(1 OD = 2x107 yeast cells) and spotting these cells onto YE6S plates or
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YE6S plates containing different concentration of HU or MMS. Wild type cells were used
as negative control while Δchk1 and Δrad3 cells as positive controls. These plates were
incubated at 30˚C for 3 days and then photographed [21].

Genetic Crossing or Complementation Test
A mutant was crossed with another strain or mutant to determine if they are allelic. Same
number of cells of the two strains/mutants with opposite mating type were spotted over
each other on ME plates. The plates were incubated at 25˚C for 4 days and then replicated
onto YE6S plates containing HU and phloxin B. The HU resistant spots suggest that the
two mutants have mutations in different genes (not allelic). Sensitive spots indicate that the
mutants being crossed likely have mutations in the same genes [35, 36].

Backcross of Mutants
The primary mutants which likely have multiple by-stander mutations in the genome is
usually backcrossed with the parental strains for three times. When backcrossing, opposite
mating type and a different ade6 allele of the mutants are selected. Opposite mating type
is required for subsequent backcrosses while ade6 is used as an indicator of successful
crossing. In medium containing a minimal amount of adenine, the two alleles of ade6 give
rise to different color (M210 – darker red, M216 - pink). For example, all non-chk mutants
were derived from YJ374, therefore they were all h+ mating type and ade6-M216. When
the mutants were backcrossed for the first time, they were mated with APS15 strain (hmating type and ade6-M210). Same number of two mutants or strains were patched on ME
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plates and mixed with sterile water, incubated at 25ºC for 2-3 days. Presence of asci, packet
of 4 spores formed after meiosis was examined microscopically to confirm the successful
mating. The asci were digested using the enzyme helicase to release the spores. These
spores were washed with 1.0% SDS once and water twice. The spores were counted using
hematocytometer and ~500 spores were spread on YE6S plates. The plates were incubated
at 30˚C for 3-5 days for the spores to germinate and form colonies. These plates were
replica plated on YE6S plates containing HU and YE6S plates lacking adenine. Comparing
the HU sensitivity and the redness of the colonies, the HU sensitive colonies with ade6
allele as of the wild type used were selected and streaked on another YE6S plate. After
repeating this procedure three times, h+ and h- mating types of each non-chk mutant strain
was collected [35, 36, 37, 38].

Identification of the New HU-Sensitive Mutants erg25 and erg7
The backcrossed mutants were transformed with a genomic library that had ura4 gene as a
selectable marker. The colonies grown on EMM plates lacking uracil were selected and the
plasmid DNAs were recovered from these yeast colonies with conferred HU resistance.
These plasmids were digested with the restriction enzymes EcoRI and BamHI followed by
analysis in an electrophoresis gel. The bands obtained were compared and classified into
different groups. From each group, a representative plasmid was selected, transformed
back into the mutant and the effect on HU resistance on these mutant cells were confirmed.
The plasmids that suppressed the cell-killing effect partially or completely were selected
for DNA sequencing. The genes involved within the sequences were compared, which
identified erg25 and erg7 genes.
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Identification of the Mutations
The genomic DNAs from the mutants M7 (erg7) and M38 (erg25) were extracted and
purified. Based on the sequences of the identified genes, gene cloning and sequencing
primers were designed that amplified a 3930 bp PCR product for erg7 and 2357 bp product
for erg25. The conditions used for PCR amplification were 94ºC denaturation temperature,
55ºC annealing temperature and 72ºC as extension temperature for 2 minutes and 30
seconds (30 cycles) using a Thermal Cycler. The PCR product was gel purified for
sequencing to identify the mutations.
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Table 1: List of S. pombe strains used in the study
Strain

Genotype

Source

YJ374

h+ cds1-6his2HA(int) leu1-32 ura4-D18 ade6-M216

Xu Lab

APS15

h- cds1-6his2HA(int) leu1-32 ura4-D18 ade6-M210

Xu Lab

APS16
APS17
NR1826
TK197

h+ cds1-6his2HA(int) leu1-32 ura4-D18 ade6-M210
h- cds1-6his2HA(int) leu1-32 ura4-D18 ade6-M216
h- ∆rad3::ura4+ leu1-32 ura4-D18 ade6-M210
h+ ∆chk1::ura4+ leu1-32 ura4-D18 ade6-M210
h+ erg11(G189D):kanR leu1-32 ura4-D18 adeM216
h- erg11(G189D):kanR leu1-32 ura4-D18 ade-M210
h+ hus168[ccr1(W511Opal) cds1-6his2HA(int) leu132 ura4-D18 ade-M210
h- hus168[ccr1(W511Opal) cds1-6his2HA(int) leu132 ura4-D18 ade-M216
h+ hcs1-1 cds1-6his2HA(int) leu1-32 ura4-D18 adeM210
h- hcs1-1 cds1-6his2HA(int) leu1-32 ura4-D18 adeM216
h+ hem13(T263I) cds1-6his2HA(Int) (pIRT-2U?)
leu1-32 ura4-D18 ade6-M21(?)
h- hem13(T263I) cds1-6his2HA(Int) (pIRT-2U?)
leu1-32 ura4-D18 ade6-M21(?)
h+ mvd1(V201A) cds1-6his2HA(Int) (pIRT-2U?)
leu1-32 ura4-D18 ade6-M21(?)
h- mvd1(V201A) cds1-6his2HA(Int) (pIRT-2U?)
leu1-32 ura4-D18 ade6-M21(?)

Xu Lab
Xu Lab
P. Russell Lab
T. Kelly Lab

YJ1298
YJ1299
YJ1491
YJ1492
husE62
husE62
YJ1460
YJ1461
YJ1462
YJ1463
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Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab

Table 2: List of PCR and sequencing primers used in the study
Name
SpErg7(P)SphI-f
SpErg7(T)KpnI-b
SpErg7(400-421)f
SpErg7(594-573)b
SpErg7(871-892)f
SpErg7(1432-53)f
SpErg7(1868-88)f
SpErg25(P)SphI-f
SpErg25(T)SacI-b
SpErg25(367-391)f
SpErg25(611-588)b
pIRTf
ura4-prom-b2
MP
MM
MT

Sequence (5’ -> 3’)
aggtGCatgcttcagataaggaagc
ggaaGgtacctgctctcttgaggg
AGGTTGGGCTCCAGAAATTATC
GCTCCTCCAAGTTCATGTAATC
TACGATTAGTGATGTGGACCTC
ACTCAAGGTTATACGGTGTCAG
GTTCTTTGGCATCAGCCGGTC
agagGCAtgccgatcattcagcctcatc
aaagGAGctctgaacattatttgttaag
CTTTCTACCTCTGTTCCCTTCCCTC
CACCACATCAAAGGAACAAAGACG
CTTAGGGATTCTATGCAAAACC
CCTATTTAGAGAAAGAATGCTGAG
ACGGTAGTCATCGGTCTTCC
TACGTTCAGTAGACGTAGTG
AGAAGAGAGAGTAGTTGAAG

Note
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Sequencing
Sequencing
Sequencing
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Sequencing
Sequencing
Mating type PCR
Mating type PCR
Mating type PCR

Table 3: List of plasmids used in the study
Name
pYJ1544
pYJ1699
pYJ1743
pYJ1277
APS51
pIRT-2U
pIRT-2L

Description
prom+erg11-3HA-nmtTERM/LEU2
pIRT-2L+prom+Ccr1+term(SphI-SacI)amp
pIRT-2L+prom-hcs1-term(PstI-SacI)LEU2
pIRT-2U+prom+Suc22+term(BamHISalI)/ura4+
Prom-hem13+-3HA/LEU2
ura4+ Vector
leu2 vector
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Source
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab
Xu Lab

RESULTS
Screening for New Non-chk Mutants
In order to identify new metabolic mutations that sensitize the cells to HU, we carried out
an extensive genetic screening in the fission yeast S. pombe. These mutants were derived
from the wild type strain YJ374 pretreated with the mutagen MNNG. The HU sensitive
(hus) mutants were selected that were further classified as chk mutants or non-chk mutants.
The DNA damaging agent MMS was used for this classification because the chk hus
mutants are sensitive to MMS while the non-chk hus mutants are not. Those hus mutants
that were not sensitive to MMS were thus classified as non-chk mutants. Because
upregulation of Suc22, the RNR small subunit and the major regulation target of the DRC,
can rescue all known chk mutants, it was overexpressed in these “non-chk” mutants to
reconfirm their metabolic mutations. If the HU sensitivity of a hus mutant was suppressed
by the overexpression of Suc22, it was considered to be chk mutant, not a non-chk mutant
(Figure 5). A total of 146 primary MMS-resistant non-chk hus mutants were thus obtained.
Before this screening, three non-chk genes erg11, ccr1, and hcs1 have already been
identified whose mutations sensitize the cells to HU. These non-chk mutants were therefore
crossed with the 146 primary non-chk mutants to see whether they are allelic to the three
known non-chk genes. In this experiment, the ability of the mutant to complement the
mutation in the other mutant is recognized. Those spots which were
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Figure 5: Strategy for the screening of non-chk mutants.
The sensitivities of the primary hus mutants to MMS and HU were used to distinguish between
chk and non-chk mutants. The newly screened non-chk mutants were confirmed by upregulation
of suc22, crossed with non-chk mutants to eliminate known mutations and then backcrossed with
parental strains to remove the bystander mutations. Following the establishment of the linkage
groups, representative mutants of each group was transformed with genomic DNA expression
libraries to identify the mutated non-chk genes.
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Figure 6: Crossing the newly screened non-chk mutants with the known non-chk
mutants.
All primary non-chk mutants were crossed with the three known non-chk mutants, erg11, ccr1,
and hcs1 to identify different alleles of the three genes. Malt Extract (ME) medium plates were
used for crossing and replica plated onto YE6S medium plates with 5 mM or 7.5 mM HU.
Phloxin B dye was added into YE6S medium as an indicator of cell lethality. The sensitivity of
each crossed spot is compared with that of the spot of known non-chk mutant (top-most line).
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sensitive to HU were considered to complement the mutation in the other mutant is
recognized. Those spots which were sensitive to HU were considered to have mutations in
the same gene as the known non-chk mutant (Figure 6). As a result, 76 mutants out of the
146 non-chk mutants were identified as potential new non-chk mutants. These mutants
were then backcrossed three times with the parental strains to remove the bystander
mutations. For each mutant, both h+ and h- strains were collected after the third backcross.
Some mutants were discarded during the backcrosses because they either lost the HU
sensitivity or were unable to grow. In the end, 57 new non-chk mutants were obtained.
These mutants were reconfirmed to be resistant to MMS but were remarkably sensitive to
HU (Figure 8). We also reassessed the effect of Suc22 overexpression and found that all
mutants except YX85, YX264, YX276 and YX464 were not rescued by Suc22 (Figure
8B). This result suggests that YX85, YX264, YX276 and YX464 were likely chk mutants.
The rest of the mutants were crossed again with the known non-chk mutants and as a result,
30 potential new non-chk mutants were obtained (Figure 11).

Determination of the Linkage Groups
30 non-chk mutants were identified as potentially novel metabolic mutants that were highly
sensitive to HU. By crossing these mutants with each other or intercross, we can identify
the genetically linked mutant groups, an indication of how many genes will be identified
in this non-chk screen. This experiment follows the same principle as the complementation
test. Figure 9 shows an example of 8 non-chk mutants crossed among themselves. In this
example, 5 genetically linked groups were determined based on the
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Figure 7: Determination of the mating type of the backcrossed mutants by colony PCR
The mating type of all the backcrossed mutants was determined by colony PCR using the primers
MP, MM, and MT. The reaction conditions were denaturation temperature 95ºC, annealing
temperature 55ºC, extension temperature 72ºC for 32 cycles.
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8A)

h+ strains

h- strains
Figure 8: Drug sensitivity of the backcrossed non-chk mutants.
8A and 8B represents different collection of mutants. Drug sensitivity of the backcrossed mutants
(h+ and h- strains) and the cells overexpressing Suc22 were examined by standard spot assay and
compared with the wild type cellsYJ374 rad3 (NR1827) and chk1 (TK197) chk mutants were
included as the control.
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8B)
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Figure 9: Intercross of non-chk mutants among themselves to identify genetic linkage groups.
An example of intercross data among 8 new non-chk mutants to determine the genetic linkage among themselves. Opposite mating type of each mutants were
spotted over each other on ME plates. The plates were incubated at 25˚C for 4 days before replica plating them on phloxin B YE6S plates containing 5 mM or
7.5 mM HU. The HU sensitive spots (dark pink) indicate that the mutants are genetically linked to each other while the HU resistant spots (light pink) are not.
Schematic representation of this data is shown on the right. The grey highlights indicate sensitive spots. The genetic linkage groups were identified by comparing
the sensitivity of the crossed spots with that of the mutants alone.
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Figure 10: Intercross data compilation to identify genetic linkage groups among all 30 potentially new non-chk mutants.
Similar to figure 8, all 30 mutants were crossed among each other and 9 genetic linkage groups were identified (see below).
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•

Figure 11: Summary of screening of non-chk mutants.
146 non-chk mutants were obtained after mutagen treatment of YJ374. These mutants were
crossed with the known non-chk mutants to discard the alleles of those genes, which identified
72 potentially new mutants. 57 of them retained the HU sensitivity after back-cross with wildtype cells for three times. Non-chk mutant properties were reconfirmed by studying the effect
on HU sensitivity of overexpressing suc22. Finally, 9 different genetic linkage groups were
identified among the 30 non-chk mutant, indicating 9 potential mutated genes
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HU sensitivity of the crossed mutants. As a control, a mutant was crossed with the opposite
mating type of the same mutant (spots diagonal in Figure 9). Similarly, the intercross for
all 30 non-chk mutants were performed and the HU sensitivity data was compiled as shown
in Figure 10. The 9 groups of genetically linked mutants are shown below:
•

Group 1: M7, U1, YX347, YX406, YX433

•

Group 2: M9, M12

•

Group 3: U5, SN79, YX35, YX86, YX102, YX147, YX482, YX503

•

Group 4: M38, YX175

•

Group 5: YX71, YX171, YX397, YX517

•

Group 6: YX146, YX210

•

Group 7: YX348, YX499

•

Group 8: SN31

•

Group 9: YX180

From these groups, as a representative of groups 1 and 4, mutants M7 and M38 were
randomly selected for further characterization.

Identification of Plasmids that Rescue the Non-chk Mutants M7 and M38
To identify the mutations in mutant M7 and M38, S. pombe genomic expression libraries
made from the wild type strain TK1 were transformed into the two mutants. The expression
vector used for making this library was pIRT-2U, which has ura4 gene as a selective
marker. After the transformation, the cells are spread onto EMM6S medium plates lacking
uracil. The yeast colonies formed on the plate were replicated onto YE6S plates containing
5 mM HU to screen for those with conferred HU resistance. A total of approximately
20,000 colonies for each mutant were screened and 20 HU resistant yeast colonies were
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selected. The plasmids were recovered from the selected yeast colonies. These plasmids
were amplified in E. coli followed by digestion with restriction enzymes EcoRI and
BamHI. After agarose gel electrophoresis, the pattern of bands of each recovered plasmid
were examined and compared with those obtained from the vector pIRT-2U digested with
the same restriction enzymes. Three different groups of the recovered plasmids were
determined for each mutant. A representative of each group of recovered plasmids was
then transformed back into the mutants. The HU sensitivity of the transformed mutants
was determined by spot assay using the mutant itself and wild type cells as the controls.
Plasmids p-9 and p-3 of M7 and M38 respectively completely rescued the mutants. While
plasmids p-1 and p-4 of M38 mutant partially rescued the mutant. These 4 plasmids were
therefore sequenced in order to identify the genes that are responsible for conferring the
HU resistance in the mutants.

Identification of Mutations in M7 and M38
PomBase is a database containing all genomic DNA sequence information of S. pombe.
The plasmid DNA sequences obtained at both the 5’ and 3’ end of the genomic DNA
fragment cloned on the pIRT-2U vector were used to compare with PomBase sequence
data to locate the cloned DNA segment as well as the genes on this fragment. For the
plasmids that rescue mutant M7, the erg7 gene encoding the enzyme lanosterol synthase of
the ergosterol biosynthetic pathway or ssa1 encoding the predicted heat shock protein
might be the candidate genes that are mutated in M7. (Figure 15B).
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Figure 12: Flow chart for identification of the mutated gene.
Schematic representation of the experiments to identify the mutated genes in non-chk mutants. S.
pombe genomic expression libraries derived from the wild type strain TK1were transformed into
a specific mutant to screen yeast colonies that became resistant to HU. Plasmids recovered from
the yeast colonies were transfected into ultra-competent DH5α bacteria cells and isolated. These
plasmids were digested using restriction enzymes followed by agarose gel electrophoresis.
Plasmids carrying different pieces of DNA were categorized into separate groups and a
representative from each group was transformed into the mutant. HU sensitivity was examined by
the standard spot assay. Plasmids that rescue the mutants or suppress the sensitivity of mutants to
HU were sequenced to identify the genes.
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13A)

13B)
Restriction analysis of pIRT-2U [Circular]
Incubated with BamHI + EcoRI
3 fragments generated.
1:

4,902 bp

-

From BamHI[1455]

To

EcoRI[234]

2:

1,200 bp

-

From EcoRI[234]

To

EcoRI[1434]

3:

21 bp

-

From EcoRI[1434]

To

BamHI[1455]

Figure 13: Restriction digestions of plasmids by EcoRI and BamHI.
A) The plasmids were digested and analyzed by an agarose gel electrophoresis. The pattern of
bands obtained were studied to categorize the plasmids containing common pieces of DNA
into one group.
B) Virtual digestion of the vector pIRT-2U used for making the genomic DNA expression
libraries.
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Figure 14: Spot Assay of non-chk mutants M38 and M7 to study the suppression of HU
sensitivity when transformed with selected plasmids.
After transforming with the recovered plasmids, HU sensitivity of the mutants M38 and M7, was
assessed by spot assay. wild type and rad3 cells were used as the controls.
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The ssa1 gene is not required for normal cell growth as the cells are viable in the absence
of this gene. However, deletion of ssa1 sensitizes the cells to both HU and MMS. Since
M7 is sensitive to HU but resistant to MMS, it is unlikely that ssa1 is mutated in this mutant.
On the other hand, erg7 gene is an essential gene for cell growth under normal conditions.
Our previous work has already shown that mutation in erg11 in the ergosterol pathway
sensitizes S. pombe to HU, it is likely that M7 contains a mutation in erg7, not in ssa1 gene.
For the plasmids that rescue the mutant M38, three candidate genes were identified. They
are SPAC630.07c, an uncharacterized gene (viable on gene deletion), mug58 encoding a
protein predicted to be from the GLYK kinase family involved in nucleotide metabolism
(viable on gene deletion) and erg25 gene encoding the predicted C-4 methyl sterol oxidase
in the ergosterol biosynthetic pathway (inviable on gene deletion) (Figure 15A). Since the
metabolic mutations in ergosterol biosynthesis are known causes of HU sensitivity, it is
likely that erg25, not the uncharacterized gene SPAC630.07c or mug58, is mutated in M38.
Furthermore, since erg7 and erg25 are essential genes for cell survival, it is likely the
mutations in these two genes are hypomorphic.

Identification of the Missense Mutations in erg7 and erg25 genes in M7 and M38
Based on the sequences of erg7 and erg25, primers were designed for cloning these genes
from the mutants M7 and M38 by using the softwares MacVector and Serial Cloner.
pIRT-2U vector was used to clone the erg7 and erg25 genes for expression in S. pombe.
The genomic DNA was purified from the two mutants. The erg7 and erg25 genes (erg7 –
3930 bp and erg25 – 2357 bp) were amplified by PCR using the primers and the high
fidelity Phusion polymerase. The PCR products were gel purified and subjected to
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sequencing. The DNA sequences obtained identified a single G-to-A mutation that caused
E508K amino acid change in erg7 gene product while a single C-to-T mutation that caused
S52F amino acid change in the erg25 gene product (Figure 16). As shown in Figure 16,
these mutated amino acids are highly conserved from yeast to humans.
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15A)

15B)

Figure 15: Gene identification of the mutants M7 and M38.
A) The plasmids that rescued the mutant M7 carried erg7 and ssa1.
B) The sequences obtained from those plasmids that rescued the mutant M38 carried three genes.
SPAC630.07c, erg25 and mug58.
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16A)

16B)

Figure 16: Identification of the mutations in M7 and M38.
A) DNA sequencing of the erg7 cloned from M7 identiﬁed a single G-to-A mutation that causes

E508K amino acid change in the enzyme
B) DNA sequencing of the erg25 cloned from M38 identiﬁed a single C-to-T mutation that causes
S52F amino acid change in the enzyme
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Figure 17: The mutated amino acid residues in erg7 and erg25 are highly conserved
from yeast to humans.
Regional amino acid sequences of erg7 and erg25 of S. pombe, human, rat and mouse were aligned
together. The amino acids highlighted in red box are the mutated Serine (S) and Glutamine (E)
residues in erg25 and erg7 respectively.

39

DISCUSSION
In this study, we carried out a hus genetic screen in the fission yeast S. pombe and collected
146 primary non-chk mutants in order to identify new metabolic genes whose mutations
can sensitize the cells to HU. After backcrossing with the parental strains to remove
bystander mutations, crossing with the known non-chk mutants to exclude known non-chk
mutations, and studying the rescuing effect of suc22 overexpression, 30 non-chk mutants
were selected. Further characterization of these 30 non-chk mutants will likely leads to
identification of new metabolic mutations. These 30 mutants were intercrossed, which
identified 9 genetically linked groups. We then randomly chose two mutants M7 and M38
from their representative linkage groups for further studies. These two mutants were
transformed with the S. pombe genomic expression libraries to screen those colonies with
conferred HU resistance. The plasmids were then recovered from the yeast colonies,
digested with restriction enzymes. Based on the sequencing data, we found that erg7 and
erg25 were likely mutated in M7 and M38, respectively. erg7 and erg25 are two essential
and highly conserved eukaryotic genes required for the ergosterol biosynthesis. To identify
the mutations, the genomic DNAs were purified from the two mutants as the templates for
PCRs using high fidelity DNA polymerase. The PCR products were purified by agarose
gel electrophoresis and sequenced, which identified two hypomorphic missense point
mutations in erg7 and erg25.
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The mutated residues in the two genes were found to be highly conserved from yeast to
humans. Although not confirmed yet, the E508K mutation (Glutamate to lysine change) in
lanosterol synthase erg7, significantly sensitizes S. pombe cells to chronic treatment of HU.
Lanosterol synthase cyclizes the oxidized product of squalene, 2,3-oxidosqualene, to
lanosterol which is the first cyclic compound formed in the ergosterol pathway or late
mevalonate pathway. Glutamate, a negatively charged amino acid, essential for stabilizing
protein structures or catalysis have been changed to the positively charged lysine, [39, 44],
which might affect the protein structure or decreased enzyme activity. The erg25 gene
encodes the C-4 methylsterol oxidase enzyme essential for ergosterol biosynthesis. The
serine amino acid residue was mutated to phenyl alanine residue (S52F). Serine amino acid
is usually required for protein structures, catalysis, or enzyme regulation. Replacing serine
with the hydrophobic phenyl alanine residue might disturb these processes and hence
reduced enzymatic activities. Perturbation of these enzymes may reduce the production of
the end product of this biosynthetic pathway, ergosterol, a sterol similar to mammalian
cholesterol that is required for maintaining cell membrane integrity. Decrease in the
ergosterol levels is known to affect cytokinesis in the presence of HU [21]. Further
characterization of these mutants would help us to better understand HU-induced cell
lethality in yeasts and mammalian cells.
The enzymes in sterol biosynthesis have been extensively studied, erg7 in particular, to
develop a non-statin approach for the treatment of hyperlipidemia because statins also
affect the production of the metabolic intermediates required for other biosynthetic
pathways. However, there are no FDA-approved drugs for clinical use yet that inhibits erg7
or erg25. For example, several small molecule inhibitors of erg7 RO48-8071, U-18666A,
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and

19-azasqualene-2,3,-epoxide

have

been

reported

and

6-amino-2-n-pentylthiobenzothiazole has been identified as the inhibitor erg25, [40, 45,
46].
As mentioned above, the primary target of HU is RNR. Inhibition of RNR affects the DNA
replication process, which activates the DRC to promote cell survival. In the DRC mutants,
the replication forks are unprotected by the DRC, which collapse, generating DNA damage
such as the strand breaks. Because the DRC mutants proceed in the presence of incomplete
DNA replication or DNA damage, catastrophic mitosis and DNA damage are likely the
main causes of cell death. In this study, we found two new genes in the ergosterol
biosynthesis pathway whose mutations sensitize the cells to HU. This result is consistent
with our hypothesis of an alternative mechanism that explains the HU induced cell death.
Understanding the cellular response mechanisms due to HU may prove beneficial in
expanding the therapeutic spectrum of this clinically important drug. HU is a wellestablished drug with various clinical implications. It is being used as a chemotherapy drug
and till date remains the primary drug for the treatment of sickle cell anemia. However, the
side effects and toxicities limit its clinical use. Studying the cell-killing mechanisms of HU
may therefore improve the HU-based chemotherapies by reducing the toxicities or side
effects or expand the therapeutic spectrum by developing novel drug combinations.
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Figure 18: Roles of Erg7 and Erg25 in the ergosterol biosynthesis pathway and its inhibitors.
While Erg7 encodes the enzyme lanosterol synthase, erg25 encodes C-4 methylsterol oxidase. Both
enzymes are essential for ergosterol biosynthesis and hence cell growth. Inhibitors of erg7 gene include
RO48-8071, U-18666A, 19-azasqualene-2,3-epoxide. Inhibitor of erg25 gene is 6-amino-2-npentylthiobenzothiazole.
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CONCLUSION
In this study, although not fully confirmed yet, we have identified two mutations in erg7
and erg25 genes encoding lanosterol synthase and C-4 methylsterol oxidase required for
ergosterol biosynthesis. Consistent with our previous studies on erg11-1 mutant, these
mutations likely perturb the ergosterol biosynthesis and thus sensitizes the cells to HU. The
mechanism behind this observed cytotoxicity is unlikely involved in perturbed DNA
replication as these mutants could not be rescued by overexpression of suc22. Further
characterization of these two mutants may shed new light on the incompletely understood
cell killing mechanisms of HU. As a long-term goal, results from this study may promote
therapeutic innovations for the treatment fungal infections or cancer.
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